PSA test for prostate cancer shown to have normal fluctuation

May 27, 2003

New York, N.Y., May 28, 2003 - A PSA (prostate specific antigen) blood test is part of routine prostate cancer screening for most men over 50. If the test result shows a moderately elevated PSA level, a referral for a biopsy is usually recommended. There is now evidence that suggests biopsy should not be performed until the test is repeated because PSA levels commonly fluctuate above and below the normal range.

In a study published in the May 28 Journal of the American Medical Association, researchers from Memorial Sloan-Kettering Cancer Center and colleagues studied nearly one thousand men who had five consecutive PSA tests over a four-year period. Up to one third of these men had elevated PSA levels; a finding which usually results in a referral for a prostate biopsy. However, subsequent testing of the same men a year or more later indicated that the PSA levels for half of the men had returned to normal. Had a biopsy been performed, it may have been unnecessary.

"A single, elevated PSA level does not automatically warrant a prostate biopsy," said Dr. James Eastham, a surgeon in the Department of Urology at Memorial Sloan-Kettering and the study's lead author. "We recommend having the findings confirmed by repeating the PSA test after waiting at least six weeks. Even if the repeat test shows an elevated level, prostate cancer will only be discovered in about one quarter of men who undergo biopsy."

The retrospective study looked at a population of 972 men with a median age of 62 years who participated in a national colon polyp prevention trial. These men were considered typical of the healthy male population at risk for developing prostate cancer, a disease that will be diagnosed in approximately 220,900 men this year. Annual blood samples were stored and later analyzed in order to study natural variations in PSA levels (serum prostate specific antigens circulating in the blood), a measurement frequently used in early detection programs for prostate cancer. Men who had five consecutive blood samples available over a four-year period were included in the study. While 21% had an elevated PSA (>4.0 ng/ml) at some time during the study, the level subsequently returned to normal spontaneously in nearly one half of the men and remained normal for most of them on further tests. A prostate biopsy of these men would not have been necessary.

"These natural variations in PSA detract from its use as a screening tool," said Colin Begg, Ph.D., chairman of the Department of Epidemiology and Biostatistics at Memorial Sloan-Kettering and senior author of the study. "A policy of confirming newly elevated PSA levels several weeks later may reduce the number of unnecessary procedures as well as the number of men diagnosed with a small, incidental tumor that poses no threat to life or health."

Waiting to confirm the diagnosis will not have an adverse affect on those men who actually have prostate cancer, according to Peter Scardino, MD, chairman of the Department of Urology at Memorial Sloan-Kettering. "A delay in diagnosis of a few weeks or months is unlikely to alter treatment efficacy," said Dr. Scardino.
The study co-authors include Ellyn Riedel, M.A., Moshe Shike, M.D., Martin Fleisher, Ph.D., and Liane Litkany of Memorial Sloan-Kettering; Arthur Schatzkin, M.D., DrPH and Elaine Lanza, Ph.D. of the National Cancer Institute; and the Polyp Prevention Trial Study Group. It was funded by grants from the National Cancer Institute and by CaPCURE, the Association for the Cure of Cancer of the Prostate. Memorial Sloan-Kettering Cancer Center is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.

Memorial Sloan Kettering Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to